2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 46.594 | 55.098 | 52.461 | 46.285 | 43.278 | 42.139 | 40.976 | 51.657 | 78.260 | 89.020 |
Total Income - EUR | 46.595 | 55.101 | 52.462 | 46.285 | 43.278 | 42.140 | 40.976 | 51.658 | 78.262 | 89.021 |
Total Expenses - EUR | 21.833 | 18.786 | 20.040 | 22.229 | 20.177 | 22.353 | 30.773 | 19.358 | 32.761 | 54.208 |
Gross Profit/Loss - EUR | 24.762 | 36.315 | 32.422 | 24.056 | 23.101 | 19.787 | 10.203 | 32.301 | 45.501 | 34.812 |
Net Profit/Loss - EUR | 23.364 | 34.662 | 31.897 | 23.593 | 22.668 | 19.366 | 9.938 | 31.862 | 44.718 | 33.922 |
Employees | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 0 | 3 |
Check the financial reports for the company - Criselis-Med S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 84.101 | 83.483 | 81.379 | 78.771 | 77.304 | 74.273 | 70.074 | 71.761 | 72.507 | 140.398 |
Current Assets | 55.336 | 89.580 | 96.095 | 106.399 | 126.829 | 109.420 | 119.903 | 128.144 | 143.066 | 132.046 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receivables | 10.110 | 8.526 | 12.795 | 13.655 | 14.593 | 1.941 | 3.153 | 976 | 7.451 | 10.590 |
Cash | 45.226 | 81.053 | 83.300 | 92.744 | 112.236 | 107.478 | 116.750 | 127.168 | 135.615 | 121.457 |
Shareholders Funds | 137.788 | 169.101 | 175.955 | 183.435 | 202.737 | 182.424 | 170.298 | 198.383 | 210.887 | 245.134 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 1.649 | 3.961 | 1.519 | 1.734 | 1.396 | 1.268 | 19.679 | 1.522 | 4.686 | 27.355 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8622 - 8622" | |||||||||
CAEN Financial Year |
8621
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Criselis-Med S.r.l.